Cite
HARVARD Citation
González-Juanatey, J. et al. (2020). Residual risk reduction opportunities in patients with chronic coronary syndrome. Role of dual pathway inhibition. Expert review of clinical pharmacology. 13 (7), pp. 695-706. [Online].